NetworkNewsBreaks – Vivos Therapeutics Inc. (NAS
Post# of 51
(Total Views: 184)
Posted On: 09/23/2021 4:47:49 PM
NetworkNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Forms Medical Consortium to Advance OSA Technology
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild to moderate obstructive sleep apnea (“OSA”), today announced the official formation of the Vivos Medical Consortium. According to the update, this physician working group, led by Drs. Clete Kushida of Stanford University and Cecilia Wu of the University of Alberta, will collaborate to advance Vivos’ OSA technology capabilities. “Every specialty in medicine deals with the negative impact of obstructive sleep apnea in some way, with the end stage of untreated sleep apnea including diminished quality of life, cardiac and metabolic disease and the potential for premature death,” said Dr. Wu. “Now more than ever, we are seeing the critical importance of optimizing personal health. For decades, the only treatment options for sleep apnea were limited and often invasive, but with the Vivos technology, that has changed dramatically. Our working group of physicians has been impressed by the potential impact of the Vivos technology and its applications, and I am excited to co-lead the Vivos Medical Consortium with Dr. Kushida as we help guide the company’s scientific progress and research endeavors, as well as raise further awareness of the Vivos technology within the medical arena.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild to moderate obstructive sleep apnea (“OSA”), today announced the official formation of the Vivos Medical Consortium. According to the update, this physician working group, led by Drs. Clete Kushida of Stanford University and Cecilia Wu of the University of Alberta, will collaborate to advance Vivos’ OSA technology capabilities. “Every specialty in medicine deals with the negative impact of obstructive sleep apnea in some way, with the end stage of untreated sleep apnea including diminished quality of life, cardiac and metabolic disease and the potential for premature death,” said Dr. Wu. “Now more than ever, we are seeing the critical importance of optimizing personal health. For decades, the only treatment options for sleep apnea were limited and often invasive, but with the Vivos technology, that has changed dramatically. Our working group of physicians has been impressed by the potential impact of the Vivos technology and its applications, and I am excited to co-lead the Vivos Medical Consortium with Dr. Kushida as we help guide the company’s scientific progress and research endeavors, as well as raise further awareness of the Vivos technology within the medical arena.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Vivos Therapeutics Inc. (VVOS) Stock Research Links
Scroll down for more posts ▼